Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.British-Swedish pharma giant AstraZeneca has completed its acquisition of rights to Spanish pharmaceutical firm Almirall’s respiratory franchise.
Subscribe to our email newsletter
As part of the deal, AstraZeneca agreed to pay Almirall about $875m of initial consideration, and up to $1.22bn in development, launch and sales-related milestones.
The acquisition gives AstraZeneca ownership rights for the development and commercialisation of the business which includes drugs like Eklira, Duaklir Genuair and treatments for illnesses, such as asthma and chronic obstructive pulmonary disease (COPD).
Currently, the UK firm will have the right to develop and commercialise the combination of aclidinium with formoterol (LAMA/LABA); Phase-II long-acting beta2 agonist LAS100977 (abediterol), an M3 antagonist beta2-agonist platform in pre-clinical development (LAS191351, LAS194871) and Phase I (LAS190792).
Almirall Sofotec, an Almirall subsidiary focused on the development of new proprietary devices, will also be transferred to AstraZeneca under the deal.
AstraZeneca chief executive officer Pascal Soriot said: "Respiratory disease is one of our company’s key therapeutic areas, and the combination of these exciting portfolios reinforces our long-term commitment to patients with asthma and COPD.
"Our expanded product and device offering will enable us to bring better treatment options to patients."